Free Trial
→ Crypto’s crashing…but we’re still profiting (From Crypto Swap Profits) (Ad) Buy CRMD Stock  Free CRMD Stock Alerts

CorMedix (CRMD) Financials

CorMedix logo
$7.52 +0.12 (+1.62%)
As of 04/16/2025 04:00 PM Eastern
Compare
Annual Income Statements for CorMedix

Annual Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -30 -46 -18
Consolidated Net Income / (Loss)		 -30 -46 -18
Net Income / (Loss) Continuing Operations		 -30 -46 -18
Total Pre-Tax Income 		-30 -46 -19
Total Operating Income		 -31 -49 -22
Total Gross Profit		 0.06 0.00 40
Total Revenue		 0.07 0.00 43
Operating Revenue		 0.07 0.00 43
Total Cost of Revenue		 0.00 0.00 3.19
Operating Cost of Revenue		 0.00 0.00 3.19
Total Operating Expenses		 31 49 63
Selling, General & Admin Expense		 20 18 30
Marketing Expense		 - 18 29
Research & Development Expense		 11 13 3.94
Total Other Income / (Expense), net		 0.34 2.62 3.03
Interest Expense		 0.03 0.03 0.04
Interest & Investment Income		 0.33 2.68 2.58
Other Income / (Expense), net		 0.04 -0.03 0.49
Income Tax Expense		 -0.59 0.00 -1.39
Basic Earnings per Share		 ($0.74) ($0.91) ($0.30)
Weighted Average Basic Shares Outstanding		 40.27M 50.90M 58.87M
Diluted Earnings per Share		 - ($0.91) ($0.30)
Weighted Average Diluted Shares Outstanding		 44.50M 50.90M 58.87M

Quarterly Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -6.85 -8.21 -11 -11 -9.75 -15 -14 -14 -2.77 13
Consolidated Net Income / (Loss)		 -6.85 -8.21 -11 -11 -9.74 -15 -14 -14 -2.78 13
Net Income / (Loss) Continuing Operations		 -6.85 -8.21 -11 -11 -9.74 -15 -14 -14 -2.78 13
Total Pre-Tax Income 		-6.85 -8.21 -11 -11 -9.74 -15 -16 -14 -2.78 13
Total Operating Income		 -6.96 -8.39 -11 -12 -10 -16 -17 -15 -3.29 13
Total Gross Profit		 0.01 0.03 0.00 0.00 0.00 - -0.82 0.30 11 30
Total Revenue		 0.01 0.03 0.00 0.00 0.00 - 0.00 1.31 11 31
Operating Revenue		 0.01 0.03 0.00 0.00 0.00 - 0.00 1.31 11 31
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 - 0.82 0.51 0.69 1.18
Operating Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 - 0.82 0.51 0.69 1.18
Total Operating Expenses		 6.97 8.42 11 12 10 16 16 16 14 17
Selling, General & Admin Expense		 4.63 5.58 7.61 3.75 3.74 2.58 15 7.56 6.58 0.77
Research & Development Expense		 2.34 2.84 3.41 4.79 2.66 2.29 0.84 0.65 0.73 1.73
Total Other Income / (Expense), net		 0.11 0.13 0.45 0.53 0.72 0.91 0.84 0.65 0.51 1.03
Interest Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Interest & Investment Income		 0.09 0.18 0.45 0.55 0.77 0.92 0.86 0.66 0.55 0.51
Other Income / (Expense), net		 0.02 -0.04 0.01 -0.01 -0.03 0.00 -0.00 -0.00 -0.03 0.53
Basic Earnings per Share		 ($0.17) ($0.20) ($0.24) ($0.25) ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25
Weighted Average Basic Shares Outstanding		 41.18M 40.27M 44.09M 45.37M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M
Weighted Average Diluted Shares Outstanding		 41.28M 44.50M 45.38M 54.81M 56.55M 50.90M 54.96M 55.86M 58.83M 58.87M
Weighted Average Basic & Diluted Shares Outstanding		 41.28M 44.50M 45.38M 54.81M 54.81M 54.98M 54.96M 55.86M 60.68M 0.00

Annual Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 -10 0.45 -3.07
Net Cash From Operating Activities		 -24 -38 -51
Net Cash From Continuing Operating Activities		 -24 -38 -51
Net Income / (Loss) Continuing Operations		 -30 -46 -18
Consolidated Net Income / (Loss)		 -30 -46 -18
Depreciation Expense		 0.08 0.07 0.15
Amortization Expense		 0.12 0.13 0.30
Non-Cash Adjustments To Reconcile Net Income		 4.07 5.49 6.13
Changes in Operating Assets and Liabilities, net		 1.07 2.23 -39
Net Cash From Investing Activities		 -3.71 -17 21
Net Cash From Continuing Investing Activities		 -3.71 -17 21
Purchase of Property, Plant & Equipment		 -0.22 -0.33 -0.12
Purchase of Investments		 -31 -77 -27
Sale and/or Maturity of Investments		 28 60 48
Net Cash From Financing Activities		 18 56 26
Net Cash From Continuing Financing Activities		 18 56 26
Issuance of Common Equity		 18 56 19
Other Financing Activities, net		 0.13 0.09 7.44
Effect of Exchange Rate Changes		 -0.01 0.00 -0.00
Cash Interest Paid		 0.03 0.03 0.04

Quarterly Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -5.68 -0.10 -18 -5.61 34 -9.68 -8.46 -6.71 6.75 5.36
Net Cash From Operating Activities		 -6.00 -6.15 -10 -8.57 -8.70 -11 -17 -14 -14 -5.61
Net Cash From Continuing Operating Activities		 -6.05 -6.15 -10 -8.57 -8.70 -11 -17 -14 -14 -5.75
Net Income / (Loss) Continuing Operations		 -6.85 -8.21 -11 -11 -9.74 -15 -14 -14 -2.78 13
Consolidated Net Income / (Loss)		 -6.85 -8.21 -11 -11 -9.74 -15 -14 -14 -2.78 13
Depreciation Expense		 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.08
Amortization Expense		 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.09 0.09 0.09
Non-Cash Adjustments To Reconcile Net Income		 1.35 0.87 2.22 1.06 1.00 1.22 2.44 1.26 1.23 1.19
Changes in Operating Assets and Liabilities, net		 -0.60 1.13 -2.09 1.59 -0.01 2.74 -5.35 -1.27 -12 -21
Net Cash From Investing Activities		 -0.11 -0.00 -15 -2.39 -0.59 0.60 8.94 6.27 6.32 -0.30
Net Cash From Continuing Investing Activities		 -0.11 -0.00 -15 -2.39 -0.59 0.60 8.94 6.27 6.32 -0.30
Purchase of Property, Plant & Equipment		 -0.08 -0.13 -0.01 -0.01 -0.01 -0.30 -0.06 -0.03 -0.01 -0.01
Purchase of Investments		 -8.09 -8.77 -25 -17 -18 -16 -7.69 -12 -1.67 -5.29
Sale and/or Maturity of Investments		 8.05 8.90 11 15 18 17 17 18 8.00 5.00
Net Cash From Financing Activities		 0.44 6.05 7.20 5.35 43 0.47 -0.10 1.06 14 11
Net Cash From Continuing Financing Activities		 0.44 6.05 7.20 5.35 43 0.47 -0.10 1.06 14 11
Issuance of Common Equity		 0.31 6.05 - - 43 0.43 - - 12 5.51
Other Financing Activities, net		 0.13 - 7.20 -7.16 0.02 0.03 -0.10 0.05 1.71 5.78
Effect of Exchange Rate Changes		 -0.01 0.02 0.00 0.00 -0.00 0.00 -0.00 -0.00 0.00 -0.00
Cash Interest Paid		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Annual Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 62 82 119
Total Current Assets		 60 79 115
Cash & Equivalents		 43 44 41
Restricted Cash		 0.12 0.08 0.00
Short-Term Investments		 16 32 11
Accounts Receivable		 - 0.00 52
Inventories, net		 0.00 2.11 7.60
Prepaid Expenses		 0.63 1.24 3.63
Plant, Property, & Equipment, net		 1.61 1.87 1.83
Total Noncurrent Assets		 0.88 0.74 2.44
Long-Term Investments		 0.10 0.10 0.11
Intangible Assets		 - 0.00 1.84
Other Noncurrent Operating Assets		 0.78 0.64 0.49
Total Liabilities & Shareholders' Equity		 62 82 119
Total Liabilities		 6.98 12 34
Total Current Liabilities		 6.31 11 34
Accounts Payable		 2.20 4.28 1.72
Accrued Expenses		 3.97 6.97 32
Other Current Liabilities		 0.13 0.15 0.17
Total Noncurrent Liabilities		 0.67 0.52 0.35
Other Noncurrent Operating Liabilities		 0.67 0.52 0.35
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 55 70 85
Total Preferred & Common Equity		 55 70 85
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 55 70 85
Common Stock		 330 392 424
Retained Earnings		 -275 -322 -340
Accumulated Other Comprehensive Income / (Loss)		 0.08 0.09 0.09

Quarterly Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 62 59 57 91 68 58 78
Total Current Assets		 60 57 55 89 63 53 73
Cash & Equivalents		 43 25 20 53 35 29 35
Restricted Cash		 0.11 0.13 0.09 0.08 0.08 0.00 0.00
Short-Term Investments		 16 30 33 33 23 17 11
Accounts Receivable		 0.00 - - - - 0.21 17
Inventories, net		 0.00 - - - 2.32 4.01 6.65
Prepaid Expenses		 0.55 1.05 2.14 2.39 2.46 3.37 3.09
Plant, Property, & Equipment, net		 1.50 1.61 1.60 1.59 1.91 1.92 1.90
Total Noncurrent Assets		 0.91 0.84 0.81 0.78 2.71 2.62 2.53
Long-Term Investments		 0.10 0.10 0.10 0.10 0.10 0.10 0.11
Intangible Assets		 - - - - 2.00 1.95 1.90
Other Noncurrent Operating Assets		 0.81 0.74 0.71 0.68 0.60 0.57 0.53
Total Liabilities & Shareholders' Equity		 62 59 57 91 68 58 78
Total Liabilities		 5.76 5.31 7.98 8.23 10 12 19
Total Current Liabilities		 5.06 4.67 7.39 7.67 9.53 11 18
Accounts Payable		 1.77 1.45 2.90 2.39 2.83 3.34 1.34
Accrued Expenses		 3.16 3.09 4.34 5.14 6.55 7.61 17
Other Current Liabilities		 0.13 0.14 0.14 0.15 0.15 0.16 0.16
Total Noncurrent Liabilities		 0.70 0.63 0.59 0.56 0.48 0.44 0.39
Other Noncurrent Operating Liabilities		 - 0.63 - - - 0.44 0.39
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 56 54 49 83 58 46 59
Total Preferred & Common Equity		 56 54 49 83 58 46 59
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 56 54 49 83 58 46 59
Common Stock		 323 340 346 390 394 396 412
Retained Earnings		 -267 -286 -297 -307 -336 -350 -353
Accumulated Other Comprehensive Income / (Loss)		 0.05 0.10 0.09 0.08 0.08 0.09 0.09

Annual Metrics and Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 -65.74% -100.00% 0.00%
EBITDA Growth		 -3.74% -60.58% 56.11%
EBIT Growth		 -3.83% -60.16% 55.36%
NOPAT Growth		 -4.03% -59.87% 54.34%
Net Income Growth		 -5.29% -56.02% 61.31%
EPS Growth		 0.00% 0.00% 67.03%
Operating Cash Flow Growth		 -15.13% -57.70% -31.78%
Free Cash Flow Firm Growth		 -1.79% -57.81% -69.72%
Invested Capital Growth		 -36.42% -53.29% 641.51%
Revenue Q/Q Growth		 -28.98% -100.00% 240.63%
EBITDA Q/Q Growth		 -2.16% -17.41% 57.74%
EBIT Q/Q Growth		 -2.16% -17.33% 57.12%
NOPAT Q/Q Growth		 -2.03% -17.47% 56.13%
Net Income Q/Q Growth		 -1.43% -16.45% 61.15%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -1.19% -13.57% 9.20%
Free Cash Flow Firm Q/Q Growth		 5.51% -13.40% -6.47%
Invested Capital Q/Q Growth		 -79.85% -101.22% 161.29%
Profitability Metrics		 - - -
Gross Margin		 94.29% 0.00% 92.66%
EBITDA Margin		 -46,443.53% 0.00% -49.25%
Operating Margin		 -46,819.91% 0.00% -51.43%
EBIT Margin		 -46,763.12% 0.00% -50.30%
Profit (Net Income) Margin		 -45,409.90% 0.00% -41.24%
Tax Burden Percent		 98.07% 100.00% 92.78%
Interest Burden Percent		 99.02% 94.60% 88.37%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -116.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -113.25%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 93.64%
Return on Equity (ROE)		 -50.40% -74.02% -23.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -166.09%
Operating Return on Assets (OROA)		 -46.70% 0.00% -21.77%
Return on Assets (ROA)		 -45.35% 0.00% -17.85%
Return on Common Equity (ROCE)		 -50.40% -74.02% -23.17%
Return on Equity Simple (ROE_SIMPLE)		 -53.94% -66.06% -21.18%
Net Operating Profit after Tax (NOPAT)		 -21 -34 -16
NOPAT Margin		 -32,773.94% 0.00% -36.00%
Net Nonoperating Expense Percent (NNEP)		 -13.25% -17.85% -3.56%
Return On Investment Capital (ROIC_SIMPLE)		 - -48.86% -18.49%
Cost of Revenue to Revenue		 5.71% 0.00% 7.34%
SG&A Expenses to Revenue		 30,586.61% 0.00% 68.92%
R&D to Revenue		 16,327.59% 0.00% 9.07%
Operating Expenses to Revenue		 46,914.20% 0.00% 144.09%
Earnings before Interest and Taxes (EBIT)		 -31 -49 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -30 -49 -21
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 3.41 2.73 5.63
Price to Tangible Book Value (P/TBV)		 3.41 2.73 5.76
Price to Revenue (P/Rev)		 2,871.04 0.00 10.97
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 12.93
Enterprise Value to Revenue (EV/Rev)		 1,968.73 0.00 9.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.06 -1.08 -0.83
Leverage Ratio		 1.11 1.15 1.30
Compound Leverage Factor		 1.10 1.09 1.15
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 9.34 3.17 4.94
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 9.44 6.97 3.39
Quick Ratio		 9.32 6.67 3.05
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -20 -32 -55
Operating Cash Flow to CapEx		 -11,103.54% -11,735.25% -43,735.12%
Free Cash Flow to Firm to Interest Expense		 -768.62 -937.74 -1,499.31
Operating Cash Flow to Interest Expense		 -918.60 -1,119.94 -1,390.32
Operating Cash Flow Less CapEx to Interest Expense		 -926.88 -1,129.48 -1,393.50
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.43
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.66
Fixed Asset Turnover		 0.04 0.00 23.54
Accounts Payable Turnover		 0.00 0.00 1.06
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 555.18
Days Payable Outstanding (DPO)		 215,622.77 0.00 343.19
Cash Conversion Cycle (CCC)		 -215,622.77 0.00 211.99
Capital & Investment Metrics		 - - -
Invested Capital		 -3.96 -6.07 33
Invested Capital Turnover		 -0.02 0.00 3.24
Increase / (Decrease) in Invested Capital		 -1.06 -2.11 39
Enterprise Value (EV)		 129 115 425
Market Capitalization		 188 191 477
Book Value per Share		 $1.33 $1.28 $1.44
Tangible Book Value per Share		 $1.33 $1.28 $1.41
Total Capital		 55 70 85
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -59 -76 -52
Capital Expenditures (CapEx)		 0.22 0.33 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.68 -8.06 29
Debt-free Net Working Capital (DFNWC)		 53 68 81
Net Working Capital (NWC)		 53 68 81
Net Nonoperating Expense (NNE)		 8.26 12 2.28
Net Nonoperating Obligations (NNO)		 -59 -76 -52
Total Depreciation and Amortization (D&A)		 0.21 0.21 0.46
Debt-free, Cash-free Net Working Capital to Revenue		 -8,678.15% 0.00% 66.82%
Debt-free Net Working Capital to Revenue		 81,397.21% 0.00% 185.72%
Net Working Capital to Revenue		 81,397.21% 0.00% 185.72%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($0.74) ($0.91) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding		 40.27M 50.90M 58.87M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding		 44.50M 54.98M 58.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 44.50M 54.98M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -34 -16
Normalized NOPAT Margin		 -32,773.94% 0.00% -36.00%
Pre Tax Income Margin		 -46,305.23% 0.00% -44.45%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -1,153.57 -1,428.35 -600.66
NOPAT to Interest Expense		 -808.48 -999.26 -429.87
EBIT Less CapEx to Interest Expense		 -1,161.84 -1,437.90 -603.84
NOPAT Less CapEx to Interest Expense		 -816.75 -1,008.80 -433.05
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -82.10% -47.33% -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 19.23% -8.29% -56.69% -44.91% -51.68% -86.34% -51.99% -29.08% 69.31% 187.33%
EBIT Growth		 19.05% -8.30% -56.26% -44.61% -51.28% -85.77% -51.83% -29.48% 68.36% 185.94%
NOPAT Growth		 18.72% -7.83% -56.66% -43.25% -50.35% -86.77% -51.62% -29.62% 68.59% 217.94%
Net Income Growth		 20.02% -5.36% -50.23% -48.24% -42.18% -79.73% -36.90% -25.53% 71.50% 191.26%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 70.59% 0.00%
Operating Cash Flow Growth		 -8.94% -4.86% -54.11% -56.94% -45.07% -74.59% -66.54% -63.78% -56.94% 47.75%
Free Cash Flow Firm Growth		 9.30% 0.95% -160.70% -56.32% -19.89% -83.95% -72.13% -83.70% -174.78% -193.47%
Invested Capital Growth		 20.23% -36.42% 2.34% -24.23% -37.01% -53.29% 87.29% 115.93% 517.02% 641.51%
Revenue Q/Q Growth		 -67.92% 335.70% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 777.11% 168.07%
EBITDA Q/Q Growth		 15.20% -21.69% -30.74% -7.41% 11.24% -49.49% -6.64% 8.78% 78.89% 525.33%
EBIT Q/Q Growth		 15.10% -21.55% -30.49% -7.39% 11.18% -49.26% -6.64% 8.41% 78.30% 505.46%
NOPAT Q/Q Growth		 15.52% -20.50% -31.33% -7.15% 11.33% -49.69% -6.61% 8.40% 78.52% 662.16%
Net Income Q/Q Growth		 9.88% -19.77% -28.73% -6.68% 13.57% -51.41% 1.95% 2.18% 80.38% 584.89%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -9.76% -2.66% -68.87% 17.52% -1.46% -23.55% -61.09% 18.89% 2.78% 58.87%
Free Cash Flow Firm Q/Q Growth		 -10.43% 11.34% -61.09% 0.89% 15.30% -36.02% -50.74% -5.78% -26.69% -45.28%
Invested Capital Q/Q Growth		 7.13% -79.85% 51.97% -54.87% -2.42% -101.22% 96.02% 294.22% 2,580.55% 161.29%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 78.45% 98.63% 0.00% 0.00% 0.00% 0.00% 0.00% 22.68% 94.01% 97.80%
EBITDA Margin		 -101,010.75% -28,211.21% 0.00% 0.00% 0.00% 0.00% 0.00% -1,162.91% -27.98% 44.40%
Operating Margin		 -102,126.07% -28,244.66% 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.47% -28.70% 42.12%
EBIT Margin		 -101,780.28% -28,394.28% 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.59% -28.99% 43.84%
Profit (Net Income) Margin		 -100,538.67% -27,637.70% 0.00% 0.00% 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 91.21% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.78% 97.34% 96.02% 95.39% 92.83% 94.17% 94.93% 92.48% 83.62% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -53.62% 136.68%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -52.90% 135.86%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 49.34% -112.34%
Return on Equity (ROE)		 -46.61% -50.40% -58.41% -66.62% -57.05% -74.02% -89.76% -111.55% -4.28% 24.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,401.45% -407.60% -166.09%
Operating Return on Assets (OROA)		 -136.39% -28.36% 0.00% 0.00% 0.00% 0.00% 0.00% -26.67% -4.38% 18.97%
Return on Assets (ROA)		 -134.72% -27.60% 0.00% 0.00% 0.00% 0.00% 0.00% -24.66% -3.66% 18.97%
Return on Common Equity (ROCE)		 -46.61% -50.40% -58.41% -66.62% -57.05% -74.02% -89.76% -111.55% -4.28% 24.34%
Return on Equity Simple (ROE_SIMPLE)		 -52.00% 0.00% -61.63% -75.23% -47.83% 0.00% -86.60% -115.01% -78.60% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.87 -5.87 -7.71 -8.26 -7.33 -11 -12 -11 -2.30 13
NOPAT Margin		 -71,488.25% -19,771.26% 0.00% 0.00% 0.00% 0.00% 0.00% -820.03% -20.09% 42.12%
Net Nonoperating Expense Percent (NNEP)		 -3.03% -3.75% -4.85% -5.19% -3.34% -5.60% -4.86% -7.04% -0.72% 0.83%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -15.64% - - - 15.28%
Cost of Revenue to Revenue		 21.55% 1.37% 0.00% 0.00% 0.00% 0.00% 0.00% 39.03% 5.99% 3.83%
SG&A Expenses to Revenue		 67,889.31% 18,770.79% 0.00% 0.00% 0.00% 0.00% 0.00% 578.76% 57.44% 2.51%
R&D to Revenue		 34,315.21% 9,572.50% 0.00% 0.00% 0.00% 0.00% 0.00% 49.84% 6.35% 5.62%
Operating Expenses to Revenue		 102,204.52% 28,343.29% 0.00% 0.00% 0.00% 0.00% 0.00% 1,194.16% 122.70% 55.68%
Earnings before Interest and Taxes (EBIT)		 -6.94 -8.43 -11 -12 -10 -16 -17 -15 -3.32 13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.89 -8.38 -11 -12 -10 -16 -17 -15 -3.21 14
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.07 3.41 3.48 4.43 2.51 2.73 4.02 5.24 8.10 5.63
Price to Tangible Book Value (P/TBV)		 2.07 3.41 3.48 4.43 2.51 2.73 4.16 5.47 8.37 5.76
Price to Revenue (P/Rev)		 1,268.47 2,871.04 3,251.82 5,950.42 7,044.87 0.00 0.00 185.19 37.24 10.97
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 418.06 34.12 12.93
Enterprise Value to Revenue (EV/Rev)		 633.16 1,968.73 2,285.45 4,526.62 4,142.11 0.00 0.00 150.18 33.63 9.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00
Long-Term Debt to Equity		 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.06 -1.03 -1.05 -1.04 -1.08 -1.02 -1.03 -0.93 -0.83
Leverage Ratio		 1.09 1.11 1.09 1.13 1.10 1.15 1.14 1.21 1.19 1.30
Compound Leverage Factor		 1.08 1.08 1.05 1.07 1.02 1.08 1.08 1.11 1.00 1.30
Debt to Total Capital		 1.23% 0.00% 0.00% 1.20% 0.66% 0.00% 0.81% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.23% 0.00% 0.00% 1.20% 0.66% 0.00% 0.81% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.77% 100.00% 100.00% 98.80% 99.34% 100.00% 99.18% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.02 0.00 0.00 -0.02 -0.01 0.00 -0.01 0.00 0.00 0.00
Net Debt to EBITDA		 1.97 0.00 0.00 1.37 2.08 0.00 1.07 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.02 0.00 0.00 -0.02 -0.01 0.00 -0.01 0.00 0.00 0.00
Debt to NOPAT		 -0.03 0.00 0.00 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00
Net Debt to NOPAT		 2.79 0.00 0.00 1.95 2.96 0.00 1.52 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.03 0.00 0.00 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00
Altman Z-Score		 6.82 10.51 14.93 9.35 11.25 4.51 7.19 4.10 9.61 5.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 11.79 9.44 12.15 7.39 11.61 6.97 6.65 4.79 3.96 3.39
Quick Ratio		 11.66 9.32 11.89 7.09 11.29 6.67 6.14 4.12 3.43 3.05
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.43 -4.82 -7.76 -7.69 -6.51 -8.86 -13 -14 -18 -26
Operating Cash Flow to CapEx		 -7,845.58% -4,780.27% -70,390.67% -134,829.03% -84,894.78% -3,631.15% -28,235.89% -40,357.34% -139,769.68% -56,890.63%
Free Cash Flow to Firm to Interest Expense		 -618.93 -548.72 -883.95 -1,314.10 -496.63 -1,351.17 -1,357.69 -2,154.45 -1,788.21 -2,597.87
Operating Cash Flow to Interest Expense		 -683.16 -701.33 -1,184.35 -1,465.12 -663.27 -1,639.06 -1,760.07 -2,141.54 -1,364.04 -561.06
Operating Cash Flow Less CapEx to Interest Expense		 -691.87 -716.00 -1,186.04 -1,466.21 -664.05 -1,684.20 -1,766.30 -2,146.84 -1,365.01 -562.05
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.15 0.43
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 2.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.66
Fixed Asset Turnover		 0.06 0.04 0.04 0.02 0.02 0.00 0.00 0.74 7.32 23.54
Accounts Payable Turnover		 0.04 0.00 0.00 0.00 0.00 0.00 0.38 0.43 1.08 1.06
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 174.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 555.18
Days Payable Outstanding (DPO)		 10,218.47 215,622.77 263,507.26 525,271.11 1,867,035.68 0.00 952.68 858.02 337.83 343.19
Cash Conversion Cycle (CCC)		 -10,043.60 -215,622.77 -263,507.26 -525,271.11 -1,867,035.68 0.00 0.00 -858.02 -337.83 211.99
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -2.20 -3.96 -1.90 -2.94 -3.02 -6.07 -0.24 0.47 13 33
Invested Capital Turnover		 -0.04 -0.02 -0.03 -0.01 -0.01 0.00 0.00 -1.06 2.67 3.24
Increase / (Decrease) in Invested Capital		 0.56 -1.06 0.05 -0.57 -0.81 -2.11 1.66 3.41 16 39
Enterprise Value (EV)		 58 129 132 165 123 115 175 196 429 425
Market Capitalization		 117 188 188 217 209 191 233 242 475 477
Book Value per Share		 $1.37 $1.33 $1.21 $1.08 $1.52 $1.28 $1.01 $0.80 $1.00 $1.44
Tangible Book Value per Share		 $1.37 $1.33 $1.21 $1.08 $1.52 $1.28 $0.97 $0.77 $0.97 $1.41
Total Capital		 57 55 54 50 84 70 58 46 59 85
Total Debt		 0.70 0.00 0.00 0.59 0.56 0.00 0.48 0.00 0.00 0.00
Total Long-Term Debt		 0.70 0.00 0.00 0.59 0.56 0.00 0.48 0.00 0.00 0.00
Net Debt		 -59 -59 -56 -52 -86 -76 -58 -46 -46 -52
Capital Expenditures (CapEx)		 0.08 0.13 0.01 0.01 0.01 0.30 0.06 0.03 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.51 -5.68 -3.62 -5.25 -5.28 -8.06 -4.75 -3.53 8.64 29
Debt-free Net Working Capital (DFNWC)		 55 53 52 47 81 68 54 42 55 81
Net Working Capital (NWC)		 55 53 52 47 81 68 54 42 55 81
Net Nonoperating Expense (NNE)		 1.98 2.34 2.86 3.01 2.42 3.79 2.77 3.44 0.48 -0.53
Net Nonoperating Obligations (NNO)		 -59 -59 -56 -52 -86 -76 -58 -46 -46 -52
Total Depreciation and Amortization (D&A)		 0.05 0.05 0.05 0.05 0.05 0.05 0.06 0.11 0.11 0.17
Debt-free, Cash-free Net Working Capital to Revenue		 -4,898.54% -8,678.15% -6,266.32% -14,377.30% -17,776.99% 0.00% 0.00% -270.06% 67.73% 66.82%
Debt-free Net Working Capital to Revenue		 59,284.64% 81,397.21% 90,193.71% 129,350.11% 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72%
Net Working Capital to Revenue		 59,284.64% 81,397.21% 90,193.71% 129,350.11% 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) ($0.20) ($0.24) ($0.25) ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25
Adjusted Weighted Average Basic Shares Outstanding		 41.18M 40.27M 44.09M 45.37M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.05) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 41.28M 44.50M 45.38M 54.81M 54.81M 50.90M 54.96M 55.86M 58.83M 58.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 41.28M 44.50M 45.38M 54.81M 54.81M 54.98M 54.96M 55.86M 60.68M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -4.87 -5.87 -7.71 -8.26 -7.33 -11 -12 -11 -2.30 9.06
Normalized NOPAT Margin		 -71,488.25% -19,771.26% 0.00% 0.00% 0.00% 0.00% 0.00% -820.03% -20.09% 29.49%
Pre Tax Income Margin		 -100,538.67% -27,637.70% 0.00% 0.00% 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -790.61 -960.99 -1,253.97 -2,019.82 -800.46 -2,389.80 -1,698.86 -2,334.09 -331.83 1,345.46
NOPAT to Interest Expense		 -555.30 -669.15 -878.76 -1,412.27 -558.77 -1,672.99 -1,188.91 -1,633.71 -229.95 1,292.70
EBIT Less CapEx to Interest Expense		 -799.31 -975.66 -1,255.65 -2,020.90 -801.25 -2,434.94 -1,705.09 -2,339.40 -332.81 1,344.47
NOPAT Less CapEx to Interest Expense		 -564.01 -683.82 -880.45 -1,413.36 -559.55 -1,718.13 -1,195.15 -1,639.01 -230.93 1,291.71
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About CorMedix's Financials

When does CorMedix's fiscal year end?

According to the most recent income statement we have on file, CorMedix's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has CorMedix's net income changed over the last 2 years?

CorMedix's net income appears to be on a downward trend, with a most recent value of -$17.93 million in 2024, falling from -$29.70 million in 2022. The previous period was -$46.34 million in 2023.

What is CorMedix's operating income?
CorMedix's total operating income in 2024 was -$22.36 million, based on the following breakdown:
  • Total Gross Profit: $40.28 million
  • Total Operating Expenses: $62.64 million
How has CorMedix revenue changed over the last 2 years?

Over the last 2 years, CorMedix's total revenue changed from $65.41 thousand in 2022 to $43.47 million in 2024, a change of 66,363.1%.

How much debt does CorMedix have?

CorMedix's total liabilities were at $34.19 million at the end of 2024, a 186.9% increase from 2023, and a 389.9% increase since 2022.

How much cash does CorMedix have?

In the past 2 years, CorMedix's cash and equivalents has ranged from $40.65 million in 2024 to $43.64 million in 2023, and is currently $40.65 million as of their latest financial filing in 2024.

How has CorMedix's book value per share changed over the last 2 years?

Over the last 2 years, CorMedix's book value per share changed from 1.33 in 2022 to 1.44 in 2024, a change of 7.8%.

Remove Ads

Related Companies

This page (NASDAQ:CRMD) was last updated on 4/17/2025 by MarketBeat.com Staff
From Our Partners
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...
Colonial Metals | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored